Related Experiment Video
Updated: Oct 9, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
460
Amylin as a Future Obesity Treatment
Babak Dehestani1, Nicholas Rs Stratford1, Carel W le Roux1
1Department of Metabolic Medicine, Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Dublin, Ireland.
Journal of Obesity & Metabolic Syndrome
|December 20, 2021
Summary
Amylin analogues, like pramlintide and investigational cagrilintide (AM833), show promise as chronic treatments for obesity. These medications help reduce food intake and promote significant weight loss.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Obesity is a chronic disease affecting one-third of the population, necessitating ongoing treatment strategies.
- Amylin, co-secreted with insulin, acts as a satiety signal influencing appetite and gastric emptying.
- Pharmacological amylin analogues offer potential therapeutic avenues for managing overweight and obesity.
Purpose of the Study:
- To review the efficacy, potency, and safety of amylin analogues as anti-obesity medications.
- To evaluate the therapeutic potential of pramlintide and cagrilintide (AM833) in weight management.
Main Methods:
- Narrative review of existing literature on amylin analogues.
- Analysis of clinical data regarding pramlintide's effects on glycemic control and weight.
- Examination of preclinical and clinical findings for AM833's impact on food intake and weight loss.
Main Results:
- Pramlintide, an approved diabetes treatment, demonstrates modest weight loss.
- AM833, a long-acting amylin analogue, acts as a calcitonin G protein-coupled receptor agonist.
- AM833 shows dose-dependent reduction in food intake and significant weight loss in studies.
Conclusions:
- Amylin analogues represent a promising class of drugs for treating obesity.
- Cagrilintide (AM833) is an attractive investigational treatment for obesity due to its efficacy in reducing appetite and promoting weight loss.
- Further research into amylin analogue therapies is warranted for chronic obesity management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
467
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
467
01:24Obesity
678
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
678
01:15Diabetes: Management and Pharmacotherapy
436
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
436
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
336
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
336
01:16Insulin: Dosing Regimen and Adverse Effects
299
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
299
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
10
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
10